BTG plc: Appointment of Non-executive Director
London, UK, 29 November 2010: BTG plc (LSE: BGC), the specialty pharmaceuticals company, today announces the appointment of Dr Melanie Lee CBE as a non-executive director of the Board, effective from today.
Melanie Lee is the Chief Executive Officer of Syntaxin Limited, a biotechnology company developing novel biopharmaceuticals to control cell secretion, and Founder and Director of the pharmaceutical consultancy Think10. She also chairs the board of Cancer Research Technology Limited, the cancer-focused technology development and commercialisation arm of Cancer Research UK. Melanie was formerly President of New Medicines and Executive VP R&D with UCB, having been R&D Director and a member of the board of the FTSE100 company Celltech plc before its merger with UCB.
Dr John Brown, BTG's chairman, commented: "Melanie brings a great deal of additional pharmaceutical industry experience to the Board, and we look forward to working with her as BTG continues to develop its business."
There are no further details to be disclosed in relation to paragraph 9.6.13R of the Financial Services Authority Listing Rules.
For further information contact:
BTG
Andy Burrows, Director of Investor Relations
+44 (0)20 7575 1741; Mobile: +44 (0)7990 530605
Rolf Soderstrom, Chief Financial Officer
+44 (0)20 7575 0000
Financial Dynamics
Ben Atwell
+44 (0)20 7831 3113
About BTG
BTG is an international specialty pharmaceuticals company that is developing and commercialising products targeting critical care, cancer, neurological and other disorders. The company is also seeking to acquire new products to develop and market to hospital specialists, and is building a sustainable business financed by revenues from sales of its critical care products and from royalties and milestone payments on partnered products.